Chemomab Therapeutics Announces Third Quarter 2026 Financial Results and Provides Corporate Update
Proposed merger with Scipher Medicine with plans to assess nebokitug in a Phase 2 precision medicine
Proposed merger with Scipher Medicine with plans to assess nebokitug in a Phase 2 precision medicine